Genova, Carlo
Marconi, Silvia
Chiorino, Giovanna
Guana, Francesca
Ostano, Paola
Santamaria, Sara
Rossi, Giovanni
Vanni, Irene
Longo, Luca
Tagliamento, Marco
Zullo, Lodovica
Dal Bello, Maria Giovanna
Dellepiane, Chiara
Alama, Angela
Rijavec, Erika
Ludovini, Vienna
Barletta, Giulia
Passiglia, Francesco
Metro, Giulio
Baglivo, Sara
Chiari, Rita
Rivoltini, Licia
Biello, Federica
Baraibar, Iosune
Gil-Bazo, Ignacio
Novello, Silvia
Grossi, Francesco
Coco, Simona
Funding for this research was provided by:
Ministero della Salute (5×1000 funds: 2018-2019, CO-2016-02361470, Ricerca Corrente 2022, RRC 2022)
Bristol-Myers Squibb (CA209-828-BMS)
Compagnia di San Paolo (2017-0529)
Article History
Received: 12 April 2024
Accepted: 7 July 2024
First Online: 6 August 2024
Declarations
:
: C.G. declares: Honoraria from: Amgen, Astra Zeneca, Bristol-Myers-Squibb, Eli Lilly, Merck-Sharp-Dohme, Novartis, Roche, Sanofi, Takeda, and Thermo Fisher. Research grants from: Bristol-Myers-Squibb; Italian Ministry of Health. G.R. declares: Honoraria from Bristol-Myers Squibb, Roche, and MSD. M.T. declares: Honoraria from travel, accommodation, and expenses: Roche, Bristol-Myers Squibb, Astra Zeneca, Takeda, and Eli Lilly. Honoraria as medical writer: Novartis, Amgen, and MSD. C.D. declares: Honoraria from Bristol-Myers Squibb, Roche, and Astra Zeneca. F.P. de-clares: advisory/consultant's fee from Merck Sharp Dohme, Astra Zeneca, Janssen, Amgen, Beigene, and Thermo Fisher Scientific. S.N. declares: speaker bureau/advisor’s fee from Eli Lilly, Merck Sharp Dohme, Roche, BMS, Takeda, Pfizer, Astra Zeneca, Amgen, and Boehringer Ingelheim. I.G.B declares: personal fees from BMS, MSD, Boehringer Ingelheim, Eli Lilly, and Roche. F.GR. declares: Advisory Role: Ad Hoc Advisory Boards/Consultations (last 3 years). Eli Lilly, Roche, Boehringer Ingelheim, Astra Zeneca, Pierre Fabre, BMS, MSD, Novartis, Merck, Otsuka, Novartis, and Takeda. Honoraria: Seminar/Talks to Industry (last 3 years). Eli Lilly, Roche, Boehringer Ingelheim, Astra Zeneca, Pierre Fabre, AMGEN, Celgene, BMS, and MSD. Research Funding (last 3 years) Astra Zeneca, BMS, and MSD. The other authors declare no conflict of interest.
: Written informed consent has been obtained from the patients to publish this paper.
: The study was conducted in accordance with the Declaration of Helsinki and approved by the Regional Ethics Committee (PR180REG2017; June 13, 2017).
: Informed consent was obtained from all subjects involved in the study.